Evommune Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Revenue	3	7	5
Revenue Growth (YoY)	-	40.00%	-
Gross Profit	3	7	5
Selling, General & Admin	13.88	12.77	10.85
Research & Development	65.12	64.24	32
Operating Expenses	79	77.01	42.85
Operating Income	-76	-70.01	-37.85
Interest Expense	-0.02	-0.03	-0.06
Interest & Investment Income	2.36	3.24	3.86
Other Non Operating Income (Expenses)	8.89	-0	-0
Pretax Income	-64.76	-66.81	-34.05
Net Income	-64.76	-66.81	-34.05
Preferred Dividends & Other Adjustments	1.5	1.5	-
Net Income to Common	-66.26	-68.31	-34.05
Shares Outstanding (Basic)	13	13	11
Shares Outstanding (Diluted)	13	13	11
Shares Change (YoY)	-	20.35%	-
EPS (Basic)	-5.15	-5.32	-3.19
EPS (Diluted)	-5.15	-5.32	-3.19
Free Cash Flow	-94.85	-58.28	-30.09
Free Cash Flow Per Share	-7.37	-4.54	-2.82
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-2533.20%	-1000.19%	-757.00%
Profit Margin	-2208.80%	-975.83%	-681.06%
Free Cash Flow Margin	-3161.53%	-832.61%	-601.76%
EBITDA	-74.55	-68.73	-36.85
D&A For EBITDA	1.44	1.29	1
EBIT	-76	-70.01	-37.85
Revenue as Reported	7	7	5

Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q